Uncategorized – Page 28

Merck Announces $3 Billion Cost-Cutting and Restructuring Plan

2 months ago talkbio0Tagged Drug Industry, estate, Financial cost, Keytruda, Merck, Q2 2025, restructuring, Transection (procedure)

Merck; cost cutting; restructuring; job cuts; real estate reduction; Keytruda; pharmaceutical industry; Q2 2025 financials

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

2 months ago talkbio0Tagged Afimetoran, Autoimmune Diseases, BMS-986322, Clinical Development, Immunology, Investments, Myers, squibb

Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

2 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

2 months ago talkbio0Tagged Adaptimmune, Afami-cel, biotech workforce, cell therapy sale, layoffs, restructuring, Tecelra, U.S., WorldMeds

Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel

Apellis’ Empaveli Gains FDA Approval for Broad C3 Glomerulopathy Use, Setting Up Competition with Novartis’ Fabhalta

2 months ago talkbio0Tagged Apellis, Approved, C3 glomerulopathy, Empaveli, Fabhalta, Iptacopan, Kidney Diseases, membranoproliferative glomerulonephritis, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Apellis; Empaveli; FDA approval; C3 glomerulopathy; primary immune complex membranoproliferative glomerulonephritis; Novartis; Fabhalta; pegcetacoplan; iptacopan; proteinuria; kidney disease

RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers

2 months ago talkbio0Tagged Advisory Committees, drugmakers, health disparity, HIV Prevention, Insurance, PREP gene, preventive services panel, public health policy, revamp, RFK Jr., USPSTF

RFK Jr.; preventive services panel; USPSTF; PrEP; HIV prevention; insurance coverage; public health policy; drugmakers; health disparities; revamp; task force

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma

2 months ago talkbio0Tagged biobucks, COPD, Hengrui Pharma, HRS-9821, Immunology, Licensing, Neoplasms, Nucala, PDE3/4 inhibitor, SmithKline Beecham

GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal

DTC vs. DTP: Regulatory Uncertainty & Access Challenges Drive New Go-to-Market Models (2025 Update)

2 months ago talkbio0Tagged Access, Aortic Valve Insufficiency, Artificial Intelligence, Diphtheria-Tetanus-Pertussis Vaccine, Direct-to-Consumer, direct-to-patient, Ditiocarb, DTP, formulary restrictions, go-to-market models, OOP costs, pharmaceutical marketing, regulatory uncertainty, Rx abandonment, Telemedicine, United States Food and Drug Administration

DTC (Direct-to-Consumer); DTP (Direct-to-Patient); regulatory uncertainty; access challenges; pharmaceutical marketing; go-to-market models; FDA; Rx abandonment; formulary restrictions; OOP costs; telehealth; AI in marketing

Rethinking Clinical Trial Data in the Era of Decentralization: Key Trends and Challenges (2025)

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Clinical Trials, Data Integration, Data Quality, DCT gene, decentralized, Diversity, Preventive monitoring, regulatory guidance, Remote, risk-based oversight, trials

decentralized clinical trials; DCT; data quality; patient diversity; remote monitoring; AI in trials; data integration; risk-based oversight; clinical trial data; regulatory guidance

Atai’s Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

2 months ago talkbio0Tagged Atai Life Sciences, CIAS, clinical endpoints, Clinical trial failure, Cognition, Impaired cognition, inidascamine, Recognify Life Sciences, Schizophrenia

Atai Life Sciences; Recognify Life Sciences; inidascamine; schizophrenia; cognitive impairment; Phase 2b trial; clinical trial failure; cognition; CIAS; clinical endpoints